Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has signed an extension to its exclusive licensing and partnership agreement for the USA and Canada, executed on 21 October 2024, with Cizzle Bio Inc (BIO) for its proprietary CIZ1B biomarker test to help detect early-stage lung cancer, to include the 14 Sovereign States of the Caribbean and the Cayman Islands. As a result of this increased market opportunity to bring Cizzle’s non-invasive, cost effective CIZ1B biomarker lung cancer blood test to market next year, BIO will make early payments totalling US$500,000 in July and September 2025 of the advanced minimum royalty of US$1 million previously all due on 21 January 2026.
Additionally, BIO have executed their first agreement with a CAP (College of American Pathologists) accredited laboratory partner and expect to register the CIZ1B biomarker as a CLIA (Clinical Laboratory Improvement Amendments) LDT (Laboratory Developed Test) in January 2025. Full product launch remains on track for April 2025. Details of this first agreement with a CAP accredited laboratory partner are confidential at this time and BIO expects to complete further contracts with other laboratory partners in due course.
